In the Claims:

Claim 1 (currently amended) Adhesive polymer matrix applied to a device intended for the transdermic administration of a progestomimetic ~~characterised~~ characterized in that said matrix contains one or more of the following successive layers:

- optionally a layer (1), known as an anchor layer, constituted by a silicone polymer,
- a layer (2), constituted by a silicone polymer loaded with Trimegestone and/or one or more pharmaceutically acceptable derivatives, and optionally a plasticizer ,
- optionally a layer (3), known as an adhesion layer, constituted by a silicone polymer.

Claim 2 (previously presented) Adhesive polymer matrix as defined in Claim 1, characterized in that it contains a quantity of Trimegestone of between 1% w/w and 10% w/w.

Claim 3 (previously presented) Adhesive polymer matrix according to Claim 1, characterized in that said matrix contains a single layer (2) constituted by a silicone polymer loaded with Trimegestone and/or one or more pharmaceutically acceptable derivatives and optionally a plasticizer.

Claim 4 (currently amended) Adhesive polymer matrix according to Claim 3, characterized in that it is constituted by 80 to 99% w/w of silicone polymer having ~~a strong~~ adhesive power loaded with 1 to 10% w/w of Trimegestone and/or one or more pharmaceutically acceptable derivatives and with 0 to 10% w/w of silicone fluid or diocytylohexane.

Claim 5 (currently amended) Adhesive polymer matrix according to Claim 4,

characterized in that it is constituted by 96% w/w of silicone polymer having ~~a strong~~ an instant adhesive power loaded with 3% w/w of Trimegestone and 1% w/w of silicone fluid.

Claim 6 (previously presented) Adhesive polymer matrix according to Claim 1, characterized in that said matrix contains two successive layers:

a) a first layer (2), comprising a silicone polymer loaded with Trimegestone and/or one or more pharmaceutically acceptable derivatives,

b) a second layer (3), adhesion layer in contact with the skin, also constituted by a silicone polymer.

Claim 7 (currently amended) Adhesive polymer matrix according to Claim 6, characterized in that

a) the first layer is constituted by 90 to 99% w/w of a silicone polymer having ~~a strong~~ adhesive power loaded with 1 to 10% w/w of Trimegestone and/or one or more pharmaceutically acceptable derivatives,

b) the second layer is also constituted by a silicone polymer with ~~a strong~~ adhesive power.

Claim 8 (currently amended) Adhesive polymer matrix according to Claim 7, characterized in that

a) the first layer is constituted by 97% w/w of a silicone polymer having ~~a strong~~ instant adhesive power, loaded with 3% w/w of Trimegestone,

b) the second layer is also constituted by a silicone polymer having ~~a strong~~ instant adhesive power.

Claim 9 (previously presented) Adhesive polymer matrix according to Claim 1, characterized in that said matrix contains three successive layers:

- a first layer (1), known as an anchor layer, constituted by a silicone polymer,

b) a second layer (2), constituted by a silicone polymer loaded with Trimegestone and/or or more pharmaceutically acceptable derivatives,

c) the third layer (3), the adhesion layer, which is in contact with the skin, also constituted by a silicone polymer.

Claim 10 (currently amended) Adhesive polymer matrix according to Claim 9, characterized in that

- the first layer is constituted by a silicone polymer with ~~a medium~~ adhesive power,
- the second layer is constituted by 90 to 99% w/w of a silicone polymer having ~~a strong~~ adhesive power loaded with 1 to 10% w/w of Trimegestone and/or or more pharmaceutically acceptable derivatives.
- the third layer is constituted by a silicone polymer with ~~a strong~~ adhesive power.

Claim 11 (currently amended) Adhesive polymer matrix according to Claim 9 ~~or 10~~, characterized in that

- the first layer is constituted by a silicone polymer with ~~a medium~~ instant adhesive power,
- the second layer is constituted by 91% w/w of a silicone polymer having ~~a medium~~ instant adhesive power loaded with 9% w/w of Trimegestone,
- the third layer is constituted by a silicone polymer having ~~a strong~~ instant adhesive power.

Claim 12 (currently amended) Device intended for the transdermic administration

of a progestomimetic, characterized in that it is successively constituted by:

- a protective film (a),
- a matrix as defined in Claim 1 ~~or 2~~,
- a peel-off protective film (b).

Claim 13 (currently amended) Device as defined in Claim 12, characterized in that the matrix is as defined in ~~any one of claims 3 to 5~~ Claim 3.

Claim 14 (currently amended) Device as defined in Claim 12, characterized in that the matrix is as defined in ~~any one of claims 6 to 8~~ Claim 6.

Claim 15 (currently amended) Device as defined in Claim 12, characterized in that the matrix is as defined in ~~any one of claims 9 to 11~~ Claim 9.

Claim 16 (previously presented) Device as defined in Claim 12, characterized in that it also contains a matrix loaded with oestrogen, said device being constituted by two compartments (A) and (B).

Claim 17 (currently amended) Device as defined in Claim 16, characterized in that the oestrogen compound is chosen from 17-beta-oestradiol, the esters of 17-beta-oestradiol ~~such as oestradiol valerate, cyprionate, decanoate and acetate, ethynyl oestradiol, oestrone~~ and an oestrogen of "equine origin" ~~such as Premarin®~~ or a combination of these compounds.

Claim 18 (previously presented) Device as defined in Claim 16, characterized in that the oestrogen compound is selected from 17-beta-oestradiol.

Claim 19 (previously presented) Device as defined in Claim 16, characterized in that the two compartments (A) and (B)

- are supported by the same peel-off protective film (b),
- and are separated from each other by an empty space or a barrier of a to 10 mm,
- compartment (A) containing the silicone polymer matrix, loaded with trimegestone and/or one or more pharmaceutically acceptable derivatives, as defined in any one of Claims 1 to 11,
- compartment (B) containing an adhesive polymer matrix loaded with oestrogen,
- and each of these matrices being covered respectively by a protective film (a) and (a') which are identical or different.

Claim 20 (previously presented) Device according to Claim 19, charaterized in that:

- compartment (A) contains a single-layer matrix as defined in Claim 3,
- and compartment (B) contains a single-layer matrix constituted by a 2-ethylexyl acrylate and vinyl acetate copolymer, loaded with oestradiol, and optionally a hydrophilic polymer.

Claim 21 (currently amended) Device according to Claim 19 ~~or 20~~, characterized in that:

- compartment (A) contains a single-layer matrix, as defined in Claim 4 ~~or 5~~,
- and compartment (B) contains a single-layer matrix constituted by 60 to 99% of 2-ethylhexyl acrylate (72%) and vinyl acetate (28%) copolymer loaded with 1 to 10% w/w of oestradiol and 0 to 30% w/w of polyvinylpyrrolidone.

Claim 22 (previously presented) Device according to Claim 19, characterized in that:

- compartment (A) contains a two-layer matrix as defined in Claim 6,
- compartment (B) contains a single-layer matrix constituted by a 2-ethylhexyl acrylate and vinyl acetate copolymer, loaded with oestradiol and optionally a hydrophilic polymer.

Claim 23 (currently amended) Device according to Claim 19 ~~or 22~~, characterized in that:

- compartment (a) contains a two-layer matrix, as defined in Claim 7 ~~or 8~~,
- and compartment (B) contains a single-layer matrix constituted by 60 to 99% of 2-ethylhexyl acrylate (72%) and vinyl acetate (28%) copolymer loaded with 1 to 10% w/w of oestradiol and 0 to 30% w/w of polyvinylpyrrolidone.

Claim 24 (currently amended) Device according to Claim 16, characterized in that it is constituted successively by the following elements:

a protective film (a),

a compartment (B) constituted by an adhesive polymer matrix loaded with an oestrogen ~~such as oestradiol~~,

a polyester film (c) having the same dimensions as compartment (A) and located on top of it,

a compartment (A) constituted by silicone polymer matrix loaded with Trimegestone and/or with various pharmaceutically acceptable derivatives, ~~as defined above~~, compartment (A) being smaller in size than compartment (B) for example half its size and preferably being centred in relation to compartment (B),

a peel-off protective film (b).

Claim 25 (previously presented) Device according to Claim 24, characterized in that the matrix containing the Trimegestone is a two-layer matrix as defined in Claim 6 or a three-layer matrix as defined in Claim 9.

Cancel **Claims 26** to **30.**

Claim 31 (currently amended) Device according to ~~any one of Claims 12 to 16~~ Claim 12, for use in a delivery process, either of Trimegestone and/or one or more pharmaceutically acceptable derivatives or of Trimegestone combined with an oestrogen, to a patient by application of the matrix/matrices of the device to the skin or to the mucous membranes of said patient.

Cancel **Claim 32.**